N-glycosylation inhibitors

About Phost'in Therapeutics

Phost'in Therapeutics is a clinical-stage biotech developing first-in-class oral inhibitors of aberrant N-glycosylation, a novel immune checkpoint. Its lead asset, PhOx430, is in an adaptive Phase I/II trial (PhAST) for advanced solid tumors and has shown strong preclinical efficacy with a favorable safety profile. The company has secured significant non-dilutive funding from French government initiatives and a strategic option/license agreement with Taiho Pharmaceutical, validating its platform's potential in oncology and chronic fibrosis. Backed by strong academic IP and a lean management team, Phost'in is positioned at the intersection of glycoscience and immuno-oncology.

Therapeutic Areas